Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study

The FIGO 2023 EC staging revision has resulted in significant upstaging from IA/IB to II, due to incorporation of lymphovascular space invasion, histology, and molecular profiles. No significant differences in survival were found between FIGO 2023 stage II substages, suggesting lack of discriminatory ability. Significant survival differences were seen within stages IIC and IICm_p53abn when stratified by initial FIGO 2009 substages, suggesting FIGO 2023 IIC and IICm_p53abn are heterogeneous cohorts.